|Home | About | Journals | Submit | Contact Us | Français|
Cardiac health is dependent upon the hearts' ability to utilize different substrates to support overall oxidative metabolism in order to generate ATP. Indeed a loss in plasticity in substrate preference leading to an over dependence on the metabolism of an individual category of substrates is characteristic of a variety cardiac diseases such as diabetic heart disease where fatty acid metabolism predominates and dilated cardiomyopathy where glucose is the primary metabolic substrate. Because of the pleiotropic actions of myocardial substrate metabolism, the detrimental effects on cardiac health of a loss in plasticity in substrate preference can extend well beyond impairment in energy production. Examples include perturbations in various cell signaling pathways, alterations in cell growth and decreased cell survival. Despite the rapid growth in our understanding of the relationship between altered myocardial metabolism and cardiac disease many questions remain. For example, it is still unclear what are the key determinants of changes in myocardial substrate use and when these changes do occur to what extent are they adaptive or have the propensity to become maladaptive? Are these metabolic patterns of prognostic significance? Transgenic models targeting key aspects of myocardial substrate use are providing mechanistic insights into myocardial metabolic-functional relationships in various cardiac diseases. However, the relevance of the observed phenotypes to the corresponding human condition is frequently unclear. Finally, applied genomics have identified numerous gene variants intimately involved in the regulation of myocardial substrate use. Yet, identifying the clinically relevant genetic variants remains elusive. As a consequence, there is an ever growing demand for accurate non-invasive imaging approaches of myocardial substrate metabolism that provide linkage between the bench and the bedside leading to improved patient management paradigms. In this regard, radionuclide approaches has led the way. The most notable example that has achieved clinical applicability is the the detection of ischemic but viable myocardium with PET and 18F-fluorodexoglucose (FDG) for the management of patients with ischemic cardiomyopathy. In the subsequent discussion advances in metabolic imaging using radionuclide approaches and their potential future applications in the study of cardiovascular disease are discussed.
Three methods are currently available to image myocardial metabolism noninvasively, magnetic resonance spectroscopy (MRS), single photon emission computed tomography (SPECT) and positron emission tomography (PET). A summary of each technique is listed below:
The advantages of MRS are the ability to measure multiple metabolic pathways simultaneously, the relative ease in performing serial measurements, and the lack of ionizing radiation. It can be combined with MRI permitting near simultaneous measurements of myocardial perfusion and mechanical function. A number of biologically important nuclei can be measured with MRS with phosphorous (31P) and hydrogen (1H), being the most common. The fundamental principle of MRS is that the chemical environment of nuclei induces local magnetic fields that shift their resonance frequency. Different metabolites exhibit a unique frequency shift resulting in a signal consisting of one or more discrete resonance frequencies. The Fourier transform of the acquired signal produces a spectrum with peaks at distinct frequencies. The MRS spectrum displays the signal intensity as a function of frequency measured in parts per million (ppm) relative to the frequency of a reference compound. The signal intensity at a given frequency is proportional to the amount of the respective metabolite and can be used to determine the absolute concentration of the metabolite using appropriate calibrating reference signal.1, 2
The disadvantages of MRS include low signal-to-noise, concomitant limited spatial resolution, intravoxel signal contamination and long acquisition times. Compared with nuclear imaging methods, MRS has a much lower sensitivity (detecting millimolar as opposed to nanomolar concentrations). As a consequence the initial success of imaging of cardiac metabolism using C-13 labeled agents in intact animals has not been translated to the study of humans.3 Cardiac applications for MRS become more limited as one moves from rodent to man as opposed to nuclear methods where the reverse occurs. This appears to be a function of both the higher field strength in the small bore systems and the use of radiofrequency coils that are in closer proximity to the entire heart used in small animal imaging. In contrast to rodent hearts where measurements of the entire left ventricular myocardium are obtained, measurements in human myocardium are typically limited to the anterior myocardium. Currently, only 31P and 1H have been widely used for in vivo clinical cardiac examinations focusing on myocardial energetics (31P) and lipid accumulation (1H).1, 3, 4
The advantages to SPECT for cardiac metabolic include; the inherent high sensitivity of the radionuclide method to measure metabolic processes, wide availability of the technology, with ECG-gating the ability to measure myocardial function simultaneously, and the long-physical half-life of SPECT radiotracers. The latter is an important attribute for it allows delivery of radiotracer to multiple sites which facilitates the performance of multi-center studies designed to answer clinically relevant questions about the potential utility of measurements of myocardial substrate metabolism in various cardiac diseases. Small animal SPECT and SPECT/CT systems are rapidly advancing, allowing the performance of myocardial metabolic studies in rodent models of cardiac disease. The major disadvantage of SPECT is the inability to quantify cellular metabolic processes primarily because of the technical limitations of SPECT (relatively poor temporal and spatial resolution and inaccurate correction for photon attenuation) and the complexity of the metabolism of the SPECT radiotracers relative to a metabolic process of interest.
Metabolic processes that can be measured by SPECT include (Table 1):
One major advantage of PET is a detection scheme that permits quantification of radioactivity within the field of view. A second advantage is the use of radiopharmaceuticals labeled with the positron-emitting radionuclides. These radionuclides of the biologically ubiquitous elements oxygen (15O), carbon (11C), and nitrogen (13N), as well as fluorine (18F) substituting for hydrogen, can be incorporated into a wide variety of substrates or substrate analogues that participate in diverse biochemical pathways without altering the biochemical properties of the substrate of interest (Table 1). By combining the knowledge of the metabolic pathways of interest with kinetic models that faithfully describe the fate of the tracer in tissue, an accurate interpretation of the tracer kinetics as they relate to the metabolic process of interest can be achieved. The major disadvantages of PET are its complexity in both radiotracer design and image quantification schemes and expense. Metabolic processes that are typically measured with PET are:
The heart is an omnivore capable of switching between one substrate to another for energy production depending upon numerous factors such as the plasma substrate environment, neurohumoral milieu and level of cardiac work (Figure 4).42 Control of substrate switching can either represent an acute or chronic adaptation in response to either short or prolonged alterations in the physiological environment. The inter-regulation of short-term modulation is based on an effective interplay between various substrates with the metabolism of one substrate automatically inhibiting the pathway of another substrate via rapid enzymatic changes. Such is the case of the Randle Cycle where fatty acid oxidation inhibits glucose oxidation, glycolysis and ultimately glucose uptake via the coordinated inhibition of pyruvate dehydrogenase, phosphofructokinase and hexokinase.43
In contrast, chronic metabolic adaptations reflect alterations in gene expression regulating various metabolic pathways. These changes can occur at the transcriptional and/or post-translational level through the coordinated up-regulation of enzymes and proteins in key metabolic pathways. One example is the hypoxia inducible transcription factor alpha (HIFα) which has several target genes that increase O2 delivery or survival during hypoxia such as genes involved in the up-regulation of glucose metabolism.44 Another example is the nuclear receptor peroxisome proliferator-activated receptor alpha (PPARα), which is a key regulator of myocardial fatty acid uptake, oxidation and storage.45 In diabetes mellitus, PPARα activity is increased leading to an up-regulation in genes controlling fatty acid uptake and oxidation.46 In contrast, pressure-overload hypertrophy PPARα activity is reduced leading to a down-regulation of genes controlling fat metabolism and in turn leading to an up-regulation of glucose use.47 Numerous detrimental effects ensue that extend beyond alterations in energy production and may include increases in oxygen free radical production, impaired energetics, increases in apoptosis, and the induction of left ventricular dysfunction.46, 48, 49 Discussed in the sections that follow is how metabolic imaging has helped characterize this loss of metabolic flexibility due to these chronic adaptations in various disease processes.
Marked changes in myocardial substrate metabolism occur with age. The fetal heart is typified by a preference for glucose primarily because of the relative hypoxia that occurs in utero. With birth and progression to adulthood fatty acids become the preferred energy source. In experimental models of aging the contribution of fatty acid oxidation to overall myocardial substrate metabolism declines with advancing age.50, 51 It appears the cause for the decrease in fatty acid oxidation is multi-factorial ranging from changes in mitochondrial lipid content, oxygen free radical injury, key enzyme systems, and a age-related decline in myocardial PPARα activity.52-54 Healthy older humans demonstrate a similar metabolic shift.55 However, despite the preference for glucose use, older individuals demonstrated a blunted increase in glucose utilization in response to dobutamine when compared to younger individuals. 56 Potential clinical ramifications of this blunted metabolic response include stress-related energy deprivation state in the aging heart or possibly increase the susceptibility of the heart to injury during periods of ischemia. However, these age related changes in substrate metabolism are not irreversible as the impairment in metabolic reserve can be ameliorated by endurance exercise training (Figure 5).57 Of interest, it appears the myocardial metabolic response to dobutamine following endurance exercise training is gender specific with men demonstrating an increase in myocardial glucose metabolism and a decline in fatty acid use whereas women exhibited increase in both glucose and fatty acid metabolism.
It is now apparent that gender is also a determinant of the pattern in the myocardial substrate metabolism. For example in female rats myocardial glucose metabolism was lower and fatty acid metabolism was higher compared with male rats.58, 59 These observations were confirmed in young healthy volunteers using PET with 11C-glucose and 11C-palmitate.60 Women exhibited lower levels of glucose metabolism compared with men. Although, no differences in myocardial fatty acid metabolism were noted, women also exhibited higher MVO2 compared with men as measured by PET with 11C-acetate. It appears these gender differences in substrate metabolism become more pronounced as one transitions to more pathologic conditions. For example in addition to the changes in glucose metabolism and MVO2, obese women exhibited higher fatty acid uptake and oxidation compared with obese men.61 The differences in myocardial metabolism could not be explained by differences in myocardial blood flow, insulin sensitivity, or hemodynamics. However, it should be noted that fatty acid release into the plasma is higher in women compared with men primarily due to a higher fat mass.62 Thus, differences in myocardial fatty acid delivery may be contributing to these metabolic differences. Sex hormone stimulation may also play a role since results of animal studies have shown that estrogen decreases glucose oxidation, gluconeogenesis, and glycogenolysis, and increases fatty acid oxidation in liver and skeletal muscle. 63 64 65 66 Estrogen also upregulates endogenous nitric oxide synthase which reduces GLUT-4 translocation to the cell surface, thereby inhibiting myocardial glucose uptake. 67 68 69 Indeed, in a small retrospective study PET-derived measurements of myocardial fatty acid metabolism were higher in post-menopausal women were higher compared with either post-menopausal women not receiving hormonal replacement therapy or age-matched men. 70 Although, requiring further study, these gender and age differences in metabolism may provide a partial explanation for the gender- and age-related outcome differences for various cardiovascular diseases where altered myocardial metabolism plays a role. Moreover, these observations highlight the need to account for age and gender differences when performing measurements of myocardial substrate metabolism.
Cardiovascular disease is the leading cause of morbidity and mortality in patients with diabetes mellitus.71 Although numerous mechanisms such as increased prevalence of hyperlipidemia and hypertension, impaired fibrinolysis, abnormal myocardial endothelial function, and reduced sympathetic neuronal function are likely responsible, there is extensive evidence to suggest that abnormalities in myocardial substrate metabolism also contribute to the increased cardiac risk. 72, 73 As mentioned previously the overdependence on fatty acid metabolism and a decrease in glucose use typifies the metabolic phenotype in diabetes. This increase in fatty acid metabolism reflects in large part the effects of peripheral insulin resistance which increase plasma fatty acid levels resulting in increased fatty acid delivery to the myocardium. This results increased myocardial fatty acid uptake which activates key transcriptional pathways such as the PPARα/PGC-1 signaling network resulting in further myocardial fatty acid uptake and oxidation.74-76. Both insulin-mediated glucose transport and glucose transporter expression decline in diabetes mellitus. However, rates of myocardial glucose uptake are frequently normal due to the presence of hyperglycemia. The increase in myocardial fatty acid metabolism results in increased citrate levels which inhibit phosphofructokinase. Glucose oxidation is inhibited at the level of pyruvate dehydrogenase complex due to increased mitochondrial acetyl-CoA levels and the phosphorylation of pyruvate dehydrogenase kinase 4 by PPARα activation. Consequently, the maintenance of myocardial glucose uptake but a decrease in its downstream metabolism results in an accumulation of glucose metabolites. Potential detrimental effects associated with this shift in metabolism include: impaired mechanical function due to the inability to increase glucose metabolism in response to increase myocardial work, depletion of tricarboxylic acid cycle intermediates due to reduced anapleurosis, electrical instability and apoptosis, a greater sensitivity to myocardial ischemia and myocardial lipid and glucose metabolite accumulation leading to increased apoptosis.
Small animal radionuclide imaging has helped clarify the mechanisms responsible for the metabolic alterations that occur in diabetes mellitus. For example, mice with cardiac-restricted overexpression of PPARα (a metabolic phenotype that is similar to diabetic hearts).77 demonstrate an increase in fatty acid uptake and an abnormal suppression of glucose uptake using small animal PET with 11C-palmitate and FDG. Conversely, small animal PET measurements demonstrate an increase glucose uptake and reduced fatty acid uptake in mice with cardiac-restricted overexpression of PPARβ/σ.78 Together these observations demonstrate that PPARα and PPARβ/σ drive different metabolic regulatory programs in the heart and that imaging can help characterize genetic manipulations in mouse heart. However, the small size of the mouse heart permits only semi-quantitative measurements of tracer uptake highlighting the imaging challenges that still must be overcome before quantification of metabolic processes are possible in this species. In contrast, quantitative measures of myocardial substrate metabolism are now possible with small animal PET in rat heart. Rates of myocardial glucose uptake correlate directly and closely and GLUT 4 gene expression in the Zucker-Diabetic-Fat (ZDF) rat, a model of type-2 diabetes mellitus (Figure 6).79 Moreover, rates of myocardial glucose uptake and fatty acid uptake and oxidation measured with PET in the same disease model demonstrated the importance of increased fatty acid delivery to defining the metabolic phenotype in diabetes.80
Numerous studies have utilized PET with FDG to characterize myocardial glucose metabolism in patients with diabetes mellitus. These studies have been primarily limited to PET using FDG.81-83 In general, rates myocardial glucose uptake are reduced in patients with either type 1 or type 2 diabetes mellitus compared with non-diabetics except in under conditions of marked hyperglycemia or supraphysiological levels in plasma insulin (such as occurs with a hyperinsulinemic-euglycemic clamp. Increased myocardial fatty acid uptake measured by arterial-coronary sinus balance studies has been reported in humans with type-1 diabetes mellitus without coronary artery disease.84 Although, the impact of plasma levels of free fatty acids on the level of myocardial fatty acid uptake was not determined, a negative correlation between myocardial glucose uptake and plasma fatty acid levels was observed. Recently studies using PET and 11C-plamitate and 11C-glucose in patients with type-1 diabetes mellitus have helped verify these findings noninvasively. Patients with diabetes exhibited higher levels of fatty acid uptake and oxidation compared with non-diabetics primarily due to increased plasma fatty acid levels. In contrast, glucose uptake was reduced in these patients primarily due to decreased glucose transport mechanisms.33. Consistent to what has been observed in experimental models of diabetes mellitus, the metabolic fate of extracted glucose is impaired in diabetes with reduced rates of glycolysis and glucose oxidation which become more pronounced with increases in cardiac work induced by dobutamine (Figure 7).85 However, despite the overdependence on fatty acid metabolism the diabetic heart still is responsive to changes in plasma insulin and fatty acid levels but at a cost. For example, higher insulin levels are needed to achieve the same level of glucose uptake and glucose oxidation compared with non-diabetics consistent with myocardial insulin resistance. In response to higher plasma fatty acid levels myocardial fatty acid uptake is increased however limitations on the downstream oxidation rate results in a greater esterification rate.85, 86
Therapeutic strategies are being designed to decrease fatty acid delivery to the in order to reduce the over dependence of the myocardium on fatty acid metabolism and perhaps improve energetics and function of the left ventricle. For example, the use of the insulin sensitizing agent troglitazone in ZDF rats reduces plasma fatty acid levels, decreases myocardial lipid accumulation, reduces apoptosis and improves left ventricular function.49 In PET with FDG studies in patients with type-2 diabetes mellitus, before and 26 weeks after treatment with rosiglitazone, demonstrated nearly a 40% increase in insulin-stimulated myocardial glucose uptake, implying reduced fatty acid uptake, which was attributed in large part to suppression in plasma fatty acid levels.87 Similar metabolic changes were not seen with the biguanide, metformin whose mechanism of action is designed to reduce hepatic glucose production. Of note, the improvement in insulin-stimulated glucose metabolism could not be predicted by changes in the plasma glucose or HgBA1C levels. These data suggest that metabolic imaging may provide unique insights into therapeutic myocardial metabolic modulation not attainable with more readily available clinical parameters are not predictive of a therapeutic response.
Given that obesity is a risk factor for type-2 diabetes mellitus it is not surprising that a significant increase in body mass index (BMI) induces marked increases in myocardial fatty acid metabolism. In either dietary-induced or transgenic models of obesity myocardial fatty acid uptake and oxidation are significantly increased.49, 88 This increase at least initially, reflects the increase in fatty acid delivery to the heart due to increased lipolysis from both visceral/abdominal and subcutaneous fat stores secondary to insulin resistance. As in diabetes mellitus the increase in cardiac fatty acid delivery initiates a cascade of events that increase myocardial fatty acid metabolism. Ultimately, fatty acid uptake may exceed oxidation leading to extracted fatty acids entering non-oxidative pathways resulting in lipid formation which can compromise cell survival and cardiac function.49
Using PET and 11C-acetate and 11C-palmitate it is now apparent that similar abnormalities in myocardial fatty acid metabolism occur in humans with obesity. For example, in otherwise healthy young obese women, myocardial fatty acid metabolism increases with an increase in BMI with the overdependence in fatty acid metabolism becoming more pronounced with worsening insulin resistance.89 There is little change in myocardial glucose metabolism. The increase in myocardial fatty acid use is paralleled by an increase in MVO2 and a decrease in energy transduction. These findings suggest that metabolic changes in obesity may play a role in the pathogenesis of cardiac dysfunction which is more pronounced in obese women.90 Of note, it appears there the myocardial metabolic response to obesity differs between women and men.61 In contrast to obese women, obese men exhibit a greater impairment in myocardial glucose metabolism per level plasma insulin, suggesting greater myocardial insulin resistance (Figure 8). In addition, obesity had less effect on myocardial fatty acid metabolism in men. In contrast, MVO2 is higher in the obese women compared with obese men. Thus it appears there appears to be a complex interplay between gender and obesity in influencing myocardial substrate metabolism.
With the induction of myocardial ischemia, fatty acid oxidation ceases and glucose becomes the primary substrate for both increased anaerobic glycolysis and for continued, albeit, diminished oxidative metabolism.91 This metabolic switch is prerequisite for continued a energy production and cell survival. When the ischemic insult is reversed, oxygen availability increases and oxidative metabolism resumes. It appears that these abnormalities in myocardial substrate metabolism may persist well after the resolution of ischemia, so called “ischemic memory”.92 Demonstration of either accelerated myocardial glucose metabolism or reduced fatty acid metabolism using FDG and BMIPP, respectively, has been used to document this phenomena. For example, increased myocardial FDG uptake has been shown in patients with unstable angina during pain-free episodes.12 Moreover, in patients with stable angina increased FDG uptake was demonstrated following exercise-induced ischemia-in the absence of either perfusion deficits or ECG abnormalities93. Similar observations have been made with SPECT using BMIPP. It is apparent that in patients with acute chest pain that abnormalities in myocardial BMIPP uptake may persist 24-36 hrs following the resolution of symptoms 94, 95 Moreover, this “metabolic fingerprint” appears superior to perfusion imaging for either identifying coronary artery disease as the cause of the chest pain or assigning prognosis.94 The persistence in the metabolic defect increases the flexibility of radiotracer administration for it allows for delivery of a unit dose after the patient has already been evaluated. This is in contrast to the use of perfusion radiotracers which frequently must be available on-site due to the narrow time window from the resolution of symptoms and normalization of the flow deficit. Based on these observations, BMIPP is currently undergoing Phase 3 evaluation for acute chest pain imaging. Recent studies also suggest that patterns of reduced fatty acid metabolism may be a marker of cardiac risk in certain high risk patient populations. For example in patients with end-stage renal disease, cardiac death was significantly associated with highly abnormal BMIPP uptake.96 Metabolic imaging with either FDG or BMIPP has also been used for direct ischemia detection during stress testing.5, 97, 98 The thought process being that abnormalities in vasodilator reserve with perfusion tracers will underestimate ischemia if oxygen demand and supply remain balanced. Results of initial studies where FDG were injected during exercise appears to support this contention with a greater detection rate for moderately severe coronary artery stenoses compared with perfusion imaging.5 Moreover, it appears defects in either glucose or fatty acid metabolism with exercise will persist for ~24hrs (Figure 9).97, 98 Taken in sum, these observations suggest metabolic imaging may provide unique role in the management of patients with ischemic heart disease. However despite these promising results, numerous questions still remain as to the optimal imaging protocols, the impact of alterations in the plasma substrate environment on diagnostic accuracy, the usefulness in diabetic patients, whether added diagnostic and prognostic information is provided over perfusion imaging, and whether this information alters clinical management.
There are numerous lines of evidence to support the notion of a relationship between between abnormalities in myocardial substrate metabolism and left ventricular hypertrophy. In experimental models of pressure-overload left ventricular hypertrophy myocardial fatty acid oxidation is decreased and there is an increase in glucose use.99, 100 Moreover, interventions that inhibit mitochondrial fatty acid β-oxidation result in cardiac hypertrophy.100 In humans, variants in genes regulating key aspects of myocardial fatty acid metabolism ranging from PPARα to various key β-oxidative enzymes are associated with left ventricular hypertrophy.101, 102
In a rat model of hypertrophy PET with FDG demonstrated myocardial glucose uptake tracked directly with increasing hypertrophy confirming this shift in substrate preference in-vivo.103. Similar results have been found in man. PET with 11C-palmitate in humans has shown the reduction in myocardial fatty acid oxidation is an independent predictor of left ventricular mass in hypertension.104 Combining measurements of left ventricular myocardial external work (either by echocardiography or MRI) with measurements of MVO2 performed by PET with 11C-acetate or 15O-oxygen, it is possible to estimate cardiac efficiency. Using this approach in patients with hypertension-induced left ventricular hypertrophy has shown that the decline in myocardial fatty acid metabolism is associated with a decline in efficiency, a condition that may increase the potential for the development of heart failure. 13, 105 Another potential application of PET is the phenotyping of patients with genetic variants related to myocyte growth. For example in patients with hypertrophic cardiomyopathy attributable to a known specific variant in the α-tropomyosin gene, it was observed that increased myocardial perfusion, fatty acid metabolism, and efficiency characterize patients with mild hypertrophy whereas these metabolic alterations decrease as hypertrophy becomes more advanced.106. Although, requiring further study in larger patient populations, this study suggests that metabolic imaging may identify relevant gene variants without waiting for more end-stage manifestations such as left ventricular remodeling and dysfunction to occur.
Perturbations in myocardial substrate metabolism have also been implicated in the pathogenesis of contractile dysfunction and heart failure. In experimental models of heart failure the progression from cardiac hypertrophy to ventricular dysfunction is paralleled by a decrease in the expression of genes encoding for enzymes regulating β-oxidation resulting in a shift in myocardial substrate metabolism to primarily glucose use, similar to that seen in the fetal heart.99, 107, 108 Paralleling these metabolic changes are the re-expression of fetal isoforms of a variety of contractile and calcium regulatory proteins program. The reactivation of the metabolic fetal gene program may have numerous detrimental consequences on myocardial contractile function ranging from energy deprivation to the inability to process fatty acids leading to accumulation of nonoxidized toxic fatty acid derivatives, resulting in lipotoxicity. Underscoring the importance of this metabolic shift in the pathogenesis of heart failure is the robust discovery and development of novel therapeutics which target specific aspects of cellular metabolism such as the partial fatty acid oxidation antagonists and the insulin sensitizer glucagon-like peptide-1.109
Both SPECT and PET techniques have documented in humans the metabolic shift associated with cardiomyopathy. For example, SPECT with BMIPP demonstrated reduced myocardial uptake and increased clearance radiotracer in patients with dilated cardiomyopathy compared with controls.110 Moreover, the magnitude of these metabolic abnormalities correlated with other measurements of heart failure severity such as left ventricular size and plasma b-natruietic peptide levels. It appears these abnormalities in BMIPP kinetics reflect the combined effects of reduced fatty acid uptake and oxidation as evidenced by PET with 11C-palmitate studies in a similar patient population. In this same study, myocardial glucose metabolsim was higher in the cardiomyopathic patients compared with controls confirming the metabolic shift.111 Similarly, PET has also been used provide mechanistic insights into the myocardial metabolic abnormalitie associated with heart failure. Rapid lowering of fatty acid delivery with acipimox results in reduced fatty acid uptake, MVO2, and cardiac work and no change cardiac efficiency in normal volunteers.106 However in patients with nonischemic dilated cardiomyopathy, there is a decrease in myocardial fatty acid uptake and cardiac work, no change in MVO2 and a decline in efficiency. Although limited by a small sample size, these results appear to reinforce to the central role of loss flexibility in myocardial substrate metabolism in the pathogenesis of heart failure with even minor changes in substrate delivery having detrimental consequences on cardiac energy transduction.
Metabolic imaging can also been used to study the effects of various treatments for cardiomyopathy. For example, treatment with the selective β-blocker metoprolol results in a reduction in oxidative metabolism and an improvement in cardiac efficiency as measured by PET in patients with heart failure.112 Cardiac efficiency has been shown to improve following either exercise training or cardiac resynchronization therapy, implicating improved myocardial energy transduction as a potential mechanism.113, 114 Moreover, normalization of the distribution of myocardial glucose metabolism may be partially responsible for the improved energetic following cardiac resynchronization therapy.115 Partial fatty acid oxidation inhibitors have been proposed for the treatment of heart failure based on the theory that decreasing myocardial fatty acid oxidation should increase the oxidation of glucose leading to a more favorable energetic state and improved left ventricular function. In support of this hypothesis is the finding that, the administration of trimetizidine to patients with dilated cardiomyopathy results in a significant improvement in left ventricular ejection fraction.106 However, the improvement in left ventricular function is paralleled by only a mild decrease in myocardial fatty acid oxidation. Thus it appears the improvement in left ventricular function reflects more than a shift in metabolism and is likely influenced by other factors such as improved whole-body insulin resistance and synergestic effects with β-blockade. In patients with dilated cardiomyopathy, it appears the fraction of myocardial glucose uptake, as measured by PET with FDG predicts the effectiveness of β-blocker therapy.116 Moreover, in patients with ischemic cardiomyopathy the extent of viable myocardium as measured with PET and FDG correlated with the hemodynamic response after cardiac resynchronization therapy suggesting a role for PET in discriminating responders from non-responders to this therapy.117 Thus, metabolic imaging can also be used to predict the response to specific therapies in heart failure patients.
Atherosclerosis is a inflammatory process characterized by cycles of intense activity and progression followed by intervals of stabilization. A common result of this process is coronary artery luminal stenosis that compromises myocardial blood flow and induces ischemia during stress. However, commonly the inciting event is acute plaque rupture with thrombosis leading to myocardial infarction and frequently, sudden cardiac death. Based on the premise that glucose metabolism is increased in activated macrophages which are a key component ofatherosclerotic plaque, FDG is being evaluated for the detection of “biologically active” atherosclerosis. Several groups have established that inflamed arterial vessels have increased uptake of FDG as measured by PET. The increased uptake has been noted in animal models of atherosclerosis, and verified in humans with atherosclerosis of the carotid artery and aorta.118-121 Moreover, a significant correlation between FDG uptake and CD68 cell staining has recently been established. It appears that vascular FDG imaging is fairly reproducible suggesting a role for monitoring of therapy.122 Indeed, a decrease in carotid artery FDG uptake is correlative with an increase in plasma high-density lipoprotein levels following statin therapy or life style modifications (Figure 10).120, 123 However many questions remain about this technique such as the site of localization of radiotracer (e.g., plaque or smooth muscle), the suitability of the method for evaluating the coronary arteries, and whether the information provides more refined risk stratification compared with other more widely applicable methods or if it alters therapy.
Despite the success of metabolic imaging in furthering our understanding of disease mechanism and in identifying and evaluating potential novel therapeutics for various forms of cardiovascular disease, advances are needed in several areas. There needs to be continued improvement in instrumentation design for imaging of humans and small animals. For example, advances in PET detector design and post-detector electronics will further increase counting statistics which would improve the ability to perform more complex compartmental modeling permitting more complete characterization of the metabolism of a given substrate. New designs in SPECT technology may permit dynamic data acquisitions permitting quantitative or semi-quantitative measurements of substrate metabolism. For small animal imaging tracer quantification is still difficult but should be facilitated with the new hybrid systems where accurate attenuation correction can be performed. There is a fundamental need for the development of new radiotracers that permit characterization of key metabolic pathways such as uptake, storage or oxidation that are linked to disease manifestations. Moreover, new radiotracers are needed to provide insights into the linkage between substrate metabolism and cell growth, cell survival and energy transduction. Ultimately, for metabolic imaging to achieve clinical relevance beyond viability detection will require the performance of appropriately powered clinical trials designed to answer key questions about the utility of metabolic imaging for diagnosis, risk stratification and monitoring of therapy in specific patient populations. To perform such studies will necessitate the development of radiotracers radiolabeled with either F-18 or I-123 and readily exportable image analysis schemes. However once these challenges are met, metabolic imaging will be positioned as an indispensible tool for the management of the cardiac patient.
This work was supported in part by PO1-HL13851, R01-HL73120 and RO1-HL69100